Skip to content
OpenCapital
Get started

ArriVent BioPharma, Inc. AVBP Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)

Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$221.17M-38.3%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$276.8M+21.8%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$1.18B-0.2%

Other financials

Income statement

See full
Operating income-$46.1M+30.9%
Net income-$43.3M+32.7%
EPS (diluted)-$0.96+49.5%

Balance sheet

See full
Cash & equivalents$62.1M+24.5%
Total debt$419.0K+204%
Total equity$324.0M+60.0%
Total assets$349.3M+62.1%

Cash flow

See full
Operating cash flow-$41.9M+38.4%

Valuation

See full
Market cap$1.49B+62.1%
Enterprise value$1.43B+65.4%

Returns & leverage

See full
Return on equity-55.2%+8.0pp
Debt / equity0×0.0×
Current ratio14×-0.4×

Where this comes from

Reported directly by ArriVent BioPharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about ArriVent BioPharma, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ArriVent BioPharma, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
ArriVent BioPharma, Inc. (AVBP) reported short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) of $264.28M in Q1 2026.
How has ArriVent BioPharma, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) changed year-over-year?
ArriVent BioPharma, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) increased by 109.4% year-over-year, from $126.21M to $264.28M.
What does short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) mean?
This represents financial instruments held by the company with maturities greater than one year that are intended to be held for investment purposes rather than immediate liquidity. These assets are often managed to generate returns on excess cash while maintaining a degree of flexibility for future capital needs. It may include restricted assets associated with specific consolidated entities.